HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The efficacy and safety of extended-release methylphenidate following traumatic brain injury: a randomised controlled pilot study.

AbstractOBJECTIVE:
To investigate the feasibility, safety and efficacy of extended-release methylphenidate in enhancing processing speed, complex attentional functioning and everyday attentional behaviour after traumatic brain injury.
DESIGN:
Seven week randomised, placebo-controlled, double-blind, parallel pilot study.
SETTING:
Inpatient and outpatient Acquired Brain Injury Rehabilitation Program.
PARTICIPANTS:
Eleven individuals with reduced processing speed and/or attention deficits following complicated mild to severe traumatic brain injury.
INTERVENTIONS:
Participants were allocated using a blocked randomisation schedule to receive daily extended-release methylphenidate (Ritalin® LA at a dose of 0.6 mg/kg) or placebo (lactose) in identical capsules.
MAIN OUTCOMES:
Tests of processing speed and complex attention, and ratings of everyday attentional behaviour were completed at baseline, week 7 (on-drug), week 8 (off-drug) and 9 months follow-up. Vital signs and side effects were monitored from baseline to week 8.
RESULTS:
Three percent ( n = 11) of individuals screened participated (mean post-traumatic amnesia duration = 63.80 days, SD = 45.15). Results were analysed for six and four individuals on methylphenidate and placebo, respectively. Groups did not differ on attentional test performance or relative/therapist ratings of everyday attentional behaviour. One methylphenidate participant withdrew due to difficulty sleeping. Methylphenidate was associated with trends towards increased blood pressure and reported anxiety.
CONCLUSION:
Methylphenidate was not associated with enhanced processing speed, attentional functioning or everyday attentional behaviour after traumatic brain injury. Alternative treatments for attention deficits after traumatic brain injury should be explored given the limited feasibility of methylphenidate in this population.
AuthorsAlicia R Dymowski, Jennie L Ponsford, Jacqueline A Owens, John H Olver, Michael Ponsford, Catherine Willmott
JournalClinical rehabilitation (Clin Rehabil) Vol. 31 Issue 6 Pg. 733-741 (Jun 2017) ISSN: 1477-0873 [Electronic] England
PMID27353245 (Publication Type: Journal Article, Randomized Controlled Trial)
Chemical References
  • Central Nervous System Stimulants
  • Methylphenidate
Topics
  • Adult
  • Brain Injuries, Traumatic (complications, diagnosis, drug therapy, rehabilitation)
  • Central Nervous System Stimulants (administration & dosage, adverse effects)
  • Cross-Over Studies
  • Double-Blind Method
  • Female
  • Glasgow Coma Scale
  • Humans
  • Male
  • Mental Disorders (drug therapy, etiology, physiopathology)
  • Methylphenidate (administration & dosage, adverse effects)
  • Middle Aged
  • Neurological Rehabilitation (methods)
  • Neuropsychological Tests
  • Pilot Projects
  • Prognosis
  • Reference Values
  • Risk Assessment
  • Statistics, Nonparametric
  • Task Performance and Analysis
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: